Silver Falcon Plc (SILFL)

 0.000p
   
  • Closing Price Chg:
      0.000p
  • 52 Week High: 0.000p
  • 52 Week Low: 0.000p
  • Currency: UK Pounds
  • Shares Issued: 64.90m
  • Volume: 0

SILFL Overview

Hemogenyx Pharmaceuticals Plc is a biotechnology company developing novel therapies to transform bone marrow and blood stem cell transplantation, announces the readmission of its enlarged issued share capital to the standard listing segment of the Official List and to trading on the main market for listed securities of the London Stock Exchange. The Company is the holding company for Hemogenyx LLC, a US-based biotechnology company developing therapies to transform bone marrow and blood stem cell transplantation. These therapies will replace the need for existing methods of preparation of patients for a transplantation such as chemotherapy and radiation treatments, and will address the problem of finding a matching stem cell donor and reduce the risk of blood stem cell rejection after transplantation.
Competitors: Okyo Pharma Limited , Nuformix

Key Personnel

CEO: Vladislav Sandler Ph.D.
Non-Executive Chairman: Marc Feldmann
Non-Executive Dir: Peter Redmond, Alexis M. Sandler

Contact Details

Address: 6th Floor, 60 Gracechurch Street, London, United Kingdom, EC3V 0HR
Website: http://hemogenyx.com/

Listings

Overseas Listings: LSE:HEMO
ISIN: GB00BYX3WZ24

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 5 minutes.

 

SILFL Market Data

Currency UK Pounds
Share Price 0.000p
Closing Price Change 0.000p
% Change 0.00 %
52 Week High 0.000p
52 Week Low 0.000p
Volume 0
Shares Issued 64.90m

Trades for --2024

Time Volume / Share Price
0 @ 0.000p

SILFL Key Personnel

CEO Vladislav Sandler Ph.D.

Top of Page